Polaryx Therapeutics (PLYX) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Polaryx Therapeutics is the larger company by market cap ($93.7 million vs $92.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLYX | UNCY |
|---|---|---|
| Share price | $1.88 | $3.36 |
| Market cap | $93.71M | $92.04M |
| 1-day change | -3.59% | -6.41% |
| YTD return | — | -41.77% |
| 1-year return | — | -28.66% |
| 5-year return | — | -86.77% |
| Forward P/E | — | 1.99 |
| EPS (TTM) | $-0.14 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-8.98M | $-26.55M |
| 52-week high | $48.91 | $8.74 |
| 52-week low | $1.85 | $3.35 |
| Distance from 52-week high | -96.16% | -61.56% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +298.94% | +745.24% |
| Average volume | 70.79K | 845.87K |
| Shares outstanding | 49.85M | 27.39M |
| Employees | 2 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
PLYX vs UNCY FAQ
Which is bigger, Polaryx Therapeutics or Unicycive Therapeutics?
Polaryx Therapeutics (PLYX) is larger, with a market capitalization of $93.71M compared with $92.04M for Unicycive Therapeutics (UNCY).
Are Polaryx Therapeutics and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.